Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.33 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4851556 | 1.00 | PTGS1 (0.52) | PTGS1ALDH1A1MAPTSLC7A5GRIK1 | |
| Lactic Acid SCHEMBL27555157 | 0.91 | TP53 (0.46) | PTGS1ALDH1A1MAPTSLC7A5GRIK1 | |
| Guanidine SCHEMBL27516721 | 0.91 | PTGS1 (0.45) | PTGS1ALDH1A1MAPTSLC7A5GRIK1 | |
| SCHEMBL27555263 | 0.89 | PTGS1 (0.43) | PTGS1ALDH1A1MAPTSLC7A5GRIK1 | |
| SCHEMBL27512274 | 0.88 | ALDH1A1 (0.42) | PTGS1ALDH1A1MAPTGRIK1SLC1A1 | |
| Hydrochloric Acid SCHEMBL27555158 | 0.88 | ALDH1A1 (0.42) | PTGS1ALDH1A1MAPTSLC7A5GRIK1 | |
| Deaminohydroxyvaline SCHEMBL28208973 | 0.86 | PTGS1 (0.41) | PTGS1ALDH1A1MAPTSLC7A5KDM4E | |
| SCHEMBL27887465 | 0.86 | ALDH1A1 (0.41) | PTGS1ALDH1A1MAPTGRIK1SLC1A1 | |
| SCHEMBL27497065 | 0.86 | PTGS1 (0.41) | PTGS1ALDH1A1MAPTKCNH2SLC1A1 | |
| SCHEMBL27857920 | 0.84 | PTGS1 (0.39) | PTGS1ALDH1A1MAPTSLC7A5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323448-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2008-01-29 | — | — | US | disclosed |
| US-7148198-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2006-12-12 | — | — | US | disclosed |
| US-20060276409-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2006-12-07 | — | — | US | disclosed |
| US-20050014702-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2005-01-20 | — | — | US | disclosed |
| US-6787522-B2 | BACTERIAL POLYPEPTIDE DEFORMYLASE (PDF) INHIBITORS, N-FORMYL HYDROXYLAMINE DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2004-09-07 | — | — | US | disclosed |
| EP-1052984-B1 | ANTIBACTERIAL AGENTS | VERNALIS OXFORD LTD (GB) | 2004-05-12 | — | — | EP | disclosed |
| US-20020165167-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2002-11-07 | — | — | US | disclosed |
| US-6423690-B1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2002-07-23 | — | — | US | disclosed |
| CN-1298299-A | Antibacterial agent | BRITISH BIOTECH PHARM (GB) | 2001-06-06 | — | — | CN | disclosed |
| EP-1052984-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999039704-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-08-12 | — | — | WO | disclosed |
| EP-0292729-B1 | PROCESS FOR SOLID PHASE PEPTIDE SYNTHESIS | BACHEM AG (CH) | 1992-04-22 | — | — | EP | disclosed |
| EP-0292729-A2 | Process for solid phase peptide synthesis | BACHEM AG (CH) | 1988-11-30 | — | — | EP | disclosed |
| US-4451456-A | Antitumor antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1984-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276409-A1 | Antibacterial agents | CBR3, CBR1, SIGMAR1 | PTGS1 3458/4885ALDH1A1 1353/4885MAPT 4693/4885 |
| US-20050014702-A1 | Antibacterial agents | CBR3, CBR1, SIGMAR1 | PTGS1 3458/4885ALDH1A1 1353/4885MAPT 4693/4885 |
| US-20020165167-A1 | Antibacterial agents | CBR1, CBR3, SIGMAR1 | PTGS1 2211/4885ALDH1A1 629/4885MAPT 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.